Filler Injuries Mark a Heavy Burden in Care-Seeking Transgender Women
Among transgender women receiving care in Mexico City, complications linked to filler injections were common, clinically disruptive, and often severe enough to require hospital treatment. The study captured a pattern that clinicians who manage gender-diverse patients should recognize immediately: a large share of prior filler exposure was tied to non-medically supervised injections, and the resulting injuries did not always surface for years.
A total of 222 transgender women with a history of filler injections were reviewed across three public referral centers in Mexico City between September 2024 and July 2025. The median age was 45 years, with an interquartile range of 38 to 52 years. Ninety-nine participants, or 44.5%, met the definition of filler-related complications, a proportion that places this problem firmly in the realm of routine clinical concern rather than isolated anecdote.
Delayed Harm After Non-Medical Injection Practice
The injected materials most often described were substances referred to as “biopolymers,” followed by injectable oils. Among participants for whom this information was available, 93% of injections had been performed by non-medical personnel. That detail is clinically important because the complications described here were not simply reactions to a product; they reflected an entire pathway of unsafe administration, variable product quality, and absent procedural oversight.
More than half of affected participants experienced symptom onset more than five years after injection. This lag matters at the bedside. Patients and clinicians may not connect a remote cosmetic or body-modification procedure with new inflammatory, infectious, migratory, or mixed symptoms years later, especially when the initial injection was done outside a formal medical setting. The long interval also suggests that biologically inert is not the same as biologically harmless. Foreign material can remain in tissue, provoking delayed inflammatory responses, chronic infection, migration, or combined syndromes that only become clinically visible once tissue injury accumulates.
Inflammatory and Mixed Presentations Dominated the Clinical Picture
The most common presentations were inflammatory or mixed forms of complication. In practical terms, that means the injuries were not limited to a single organ system or one predictable type of lesion. They spanned local tissue inflammation, infectious processes, and material migration, which can complicate evaluation and delay definitive management.
More than one-third of affected participants required hospitalization because of filler-related complications. Hospital admission signals a level of severity that goes far beyond cosmetic dissatisfaction. It points to pain, tissue injury, systemic involvement, or the need for intensive diagnostic workup and procedural intervention. For a condition arising from a procedure often sought to affirm gender expression, this is a sobering contrast: the intervention intended to support identity instead became a source of major morbidity.
The referral-center setting likely sharpened the severity profile. The cohort came from public specialty centers, which means the sample may be enriched for patients with more complex or advanced presentations. Severe cases are more likely to reach these facilities, while milder complications may remain uncounted in the community. Even with that caveat, the absolute burden was substantial, and the pattern of injury was consistent across a clinically vulnerable population.
Structural Barriers and Unsafe Access Shaped the Risk
The study places these injuries in a broader structural context. Limited access to gender-affirming healthcare, along with psychosocial and social pressures, can drive people toward body-modification practices that are more accessible than supervised medical care. When formal avenues for transition-related care are difficult to reach, injectable substances may appear to offer an affordable, immediate, and socially reinforced alternative.
That context does not reduce the clinical danger. It explains it.
In this setting, the medical problem and the public health problem are inseparable. Unsafe filler use is not only a dermatologic or procedural complication; it is a marker of inequitable access, undocumented intervention, and delayed presentation. The 93% non-medical injection rate among those with available data makes the point starkly. The injuries were happening in a space with little procedural accountability and, often, no longitudinal follow-up.
What Clinicians Need to Ask and What Systems Need to Build
The findings support a more deliberate approach to history-taking in transgender care. Patients with unexplained nodules, inflammatory masses, swelling, recurrent infection, or migration-related symptoms should be asked directly about past filler injections, including procedures performed years earlier and those obtained outside medical supervision. A negative response may be incomplete if the patient does not view these practices as medically relevant, or if the substances used were marketed under informal or misleading names.
Multidisciplinary care pathways are also necessary. Evaluation may involve infectious diseases, surgery, radiology, dermatology, and gender-affirming care services, depending on the presentation. The clinical team in such cases is not simply treating a cosmetic adverse event; it is managing chronic foreign-body complications in tissue that may be repeatedly inflamed, infected, or structurally altered.
The study also carries a policy implication that is difficult to avoid. When access to gender-affirming healthcare remains fragmented, risky alternatives fill the void. Patients then bear the burden in the form of delayed complications, hospitalization, and prolonged morbidity. Better access to supervised care would not eliminate every injury, but it could reduce the incentive to seek unregulated procedures and create earlier opportunities for counseling, safer alternatives, and prompt diagnosis.
Severe Cases May Be the Visible Tip of a Larger Problem
Because the cohort came from referral centers, the observed complication rate may overstate what would be seen in a broader community sample. Even so, the pattern is too consistent to dismiss. Nearly half of transgender women with prior filler exposure had documented complications, and a substantial fraction required hospital admission. Those figures describe a problem with real clinical consequences, not a theoretical concern.
The delayed onset of symptoms, the high rate of non-medical administration, and the predominance of inflammatory or mixed presentations all point to the same conclusion: filler-related complications can remain hidden for years before arriving in specialty care. For clinicians, that means the history of body modification must remain part of routine assessment. For health systems, it means safe access to gender-affirming services cannot be separated from prevention of avoidable harm.